Daily pill could offer new hope for weight loss in east asian adults

NCT ID NCT05132088

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This Phase 3 trial is testing whether a once-daily 50 mg semaglutide tablet can help East Asian adults with overweight or obesity lose weight. Participants will take either the active tablet or a placebo for 68 weeks, alongside lifestyle counseling on diet and physical activity. The study measures changes in body weight and the proportion of people achieving at least 5% weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide 50 mg oral tablet
What this could lead to: If successful, this could provide a convenient daily pill option for weight management in East Asian adults with overweight or obesity.
What could go wrong: The trial is still testing the drug's efficacy and safety; results may not apply to all populations, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND OBESITY

Contacts and locations

Locations

Gachon University Gil Medical Center

Incheon, 21565, South Korea
Kangbuk Samsung Hospital

Seoul, 03181, South Korea
Kyungpook National University Hospital

Daegu, 41944, South Korea
Naka Kinen Clinic_Internal medicine

Ibaraki, 311-0113, Japan
OCROM Clinic_Internal medicine

Suita-shi, Osaka, 565-0853, Japan
Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea
Shinsapporo Seiryou Hospital_General Clinical Department

Sapporo, Hokkaido, 004-0004, Japan
Takatsuki Red Cross Hospital

Osaka, 569-1045, Japan
Takatsuki Red Cross Hospital_Diabetes and Endocrine Div.

Osaka, 569-1045, Japan
The University of Osaka Hospital_Metabolic Medicine

Osaka, 565-0871, Japan
ToCROM Clinic_Internal Medicine

Tokyo, 160-0008, Japan
Tokyo Center Clinic

Tokyo, 103-0028, Japan
Tokyo Center Clinic_Internal Medicine

Tokyo, 103-0028, Japan
Toranomon Hospital, Endocrinology and Metabolism

Minato-ku, Tokyo, 105-8470, Japan
Tsuruma Kaneshiro Diabetes Clinic_Internal medicine

Yamato-shi, Kanagawa, 242-0004, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.